Was the XERS share sale by Kevin McCulloch under a Rule 10b5-1 plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan that Kevin McCulloch adopted on September 4, 2025, as disclosed in the footnotes and affirmed by the plan checkbox.

Xeris Biopharma insider sells 15K shares at $8.49

Q: What insider transaction did XERS report for Kevin McCulloch on this Form 4?

The filing reports that Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. common stock on September 1, 2026 in an open market or private transaction, as indicated by transaction code S.

Q: At what price were the XERS shares sold by Kevin McCulloch?

The reported weighted average sale price was $8.4872 per share, with individual sale prices ranging from $8.390 to $8.600 per share, inclusive.

Q: How many XERS shares does Kevin McCulloch own after the reported sale?

After the sale, Kevin McCulloch directly owns 1,639,208 shares of Xeris Biopharma common stock. In addition, there are 25,000 shares held indirectly by his spouse, for which he disclaims beneficial ownership except for his pecuniary interest.

Q: What does the Form 4 say about Kevin McCulloch’s indirect ownership of XERS shares?

The Form 4 reports 25,000 shares of Xeris Biopharma common stock held indirectly “By Spouse.” McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.

After the Sept. 1 sale under a Rule 10b5-1 plan, he directly holds 1,639,208 shares and indirectly holds 25,000 through his spouse.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. (XERS) reported that President and Chief Operating Officer Kevin McCulloch sold 15,000 shares of common stock on September 1, 2026 at a weighted average price of $8.4872 per share, pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. Following this sale, he directly holds 1,639,208 shares of common stock and has indirect holdings of 25,000 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 2 txns

Insider McCulloch Kevin

Role See Remarks

Sold 15,000 shs ($127K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	15,000	$8.4872	$127K
holding	Common Stock ^F3	--	--	--

Holdings After Transaction: Common Stock — 1,639,208 shares (Direct); Common Stock — 25,000 shares (Indirect, By Spouse)

Footnotes (3)

F1. The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares sold: 15,000 shares of Common Stock Weighted average sale price: $8.4872 per share Price range of sales: $8.390–$8.600 per share +3 more

6 metrics

Shares sold 15,000 shares of Common Stock Sale on September 1, 2026 by Kevin McCulloch

Weighted average sale price $8.4872 per share Multiple transactions between $8.390 and $8.600 on September 1, 2026

Price range of sales $8.390–$8.600 per share Range of individual trade prices for the 15,000 shares sold

Direct holdings after transaction 1,639,208 shares of Common Stock Direct ownership by Kevin McCulloch following the September 1, 2026 sale

Indirect holdings by spouse 25,000 shares of Common Stock Indirect ownership reported as held by spouse; beneficial ownership disclaimed except for pecuniary interest

Rule 10b5-1 plan adoption date September 4, 2025 Date Kevin McCulloch adopted the trading plan under which the sale was effected

Key Terms

Rule 10b5-1 trading plan, weighted average price, beneficial ownership, pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership regulatory

"shall not be deemed an admission of beneficial ownership of all"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"

FAQ

What insider transaction did XERS report for Kevin McCulloch on this Form 4?

The filing reports that Kevin McCulloch sold 15,000 shares of Xeris Biopharma Holdings, Inc. common stock on September 1, 2026 in an open market or private transaction, as indicated by transaction code S.

At what price were the XERS shares sold by Kevin McCulloch?

The reported weighted average sale price was $8.4872 per share, with individual sale prices ranging from $8.390 to $8.600 per share, inclusive.

How many XERS shares does Kevin McCulloch own after the reported sale?

After the sale, Kevin McCulloch directly owns 1,639,208 shares of Xeris Biopharma common stock. In addition, there are 25,000 shares held indirectly by his spouse, for which he disclaims beneficial ownership except for his pecuniary interest.

What does the Form 4 say about Kevin McCulloch’s indirect ownership of XERS shares?

The Form 4 reports 25,000 shares of Xeris Biopharma common stock held indirectly “By Spouse.” McCulloch disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/01/2026 - 06:21 PM Accepted by SEC EDGAR 09/01/2026 - 06:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last)

(First)

(Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO

ILLINOIS

60607

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2026		S⁽¹⁾		15,000	D	$8.4872⁽²⁾	1,639,208	D
Common Stock								25,000⁽³⁾	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR